MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins

    C. Murray, C. Kusiak, A. Vanderbeek, D. Bertolini, E. Tramel (San Francisco, USA)

    Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…
  • 2024 International Congress

    Unraveling Plantar Pressure Dynamics in Parkinson’s Disease with Freezing of Gait: Taking Steps through Its Characters and Predictive Factors

    T. Tiraweerakhajorn, W. Phuenpathom, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To elucidate plantar pressure characteristics in different stages of PD patients who experienced FOG and identify predictive factors for alterations in plantar pressure parameters.…
  • 2024 International Congress

    First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease

    T. Lewis, B. Calamini, L. Verselis, M. Lowrey, L. Shaughnessy, J. Deranick, M. Dieter, M. Krautkramer, O. Uspenskaya, J. Sevigny (New York, USA)

    Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…
  • 2024 International Congress

    Evaluation of neuroprotective effects of doxycycline in a primate model of PD

    L. Pedrosa, L. Leal, J. Muniz, E. Del-Bel, B. Gomes, L. Krejcová (Belém, Brazil)

    Objective: To evaluate the effects of doxycycline on the outcomes of 6-OHDA-induced Parkinson's disease in Sapajus apella monkeys. Background: Doxycycline (doxy) has been reported as…
  • 2024 International Congress

    Bidirectional interplay between DBS and cognition in Parkinson’s disease: a systematic review

    V. Sisodia, A. Malekzadeh, E. Verwijk, P. Schuurman, R. de Bie, B. Swinnen (Amsterdam, Netherlands)

    Objective: To evaluate the evidence regarding (1) deep brain stimulation (DBS) effectiveness in case of postoperative cognitive deterioration, (2) the impact of preoperative cognition on…
  • 2024 International Congress

    AAV-mediated gene therapy for GBA-PD

    S. Ayloo, J. Ryu, S. Chou, C. Miller, L. Blatnik, E. Wischhof, J. Bu, W. Mccarty, L. Guo, S. Nass, C. O'Riordan, B. Elmer, C. Mueller, S. Ramachandran (Waltham, USA)

    Objective: Development of a gene therapy-based drug for treatment of GBA-PD, a genetic subtype of Parkinson’s disease Background: Mutations in GBA1, the gene encoding glucocerebrosidase…
  • 2024 International Congress

    Deep brain stimulation contact selection using Neurophysiology and Artificial intelligence

    V. Lavu, J. Cagle, T. de Araujo, C. de Hemptinne, J. Wong (Gainesville, USA)

    Objective: To develop a machine learning (ML) algorithm capable of predicting the optimal deep brain stimulation (DBS) contact based on neurophysiology. Background: DBS is an…
  • 2024 International Congress

    The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease

    O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate the plasma levels of vitamin B and homocysteine among 28 advanced PD patients with motor complications before and after continued used of…
  • 2024 International Congress

    Pathological Mechanisms Associated with Atrazine-Induced Parkinson’s Disease Pathogenesis in Rat Model: The Rescue Role of Myricetin

    C. Ikeji, E. Farombi (Ibadan, Nigeria)

    Objective: This study aimed at investigating the mechanisms involved in the pathogenesis of Parkinson’s Disease in atrazine rat model of Parkinson’s Disease and the neuroprotective…
  • 2024 International Congress

    Discriminating alpha-synuclein strains in Parkinson’s disease

    I. Schniewind, S. Bräuer, E. Dinter, BH. Falkenburger (Dresden, Germany)

    Objective: To evaluate possible differences in the biological properties of alpha-synuclein fibrils derived from different patients with Parkinson's disease. Background: Parkinson’s disease (PD) is a…
  • « Previous Page
  • 1
  • …
  • 287
  • 288
  • 289
  • 290
  • 291
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley